tiprankstipranks
Trending News
More News >
Enlivex Therapeutics Ltd (ENLV)
NASDAQ:ENLV
US Market

Enlivex (ENLV) Stock Forecast & Price Target

Compare
490 Followers
See the Price Targets and Ratings of:

ENLV Analyst Ratings

Hold
1Ratings
Hold
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Enlivex
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ENLV Stock 12 Month Forecast

Average Price Target

Based on 1 Wall Street analysts offering 12 month price targets for Enlivex in the last 3 months. The average price target is with a high forecast of and a low forecast of . The average price target represents a change from the last price of $0.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,0.9692307692307692,0.8884615384615385,0.8076923076923077,0.726923076923077,0.6461538461538462,0.5653846153846154,0.48461538461538467,0.40384615384615385,0.32307692307692304,0.24230769230769234,0.16153846153846152,0.0807692307692307,{"y":null,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,0.9692307692307692,0.8884615384615385,0.8076923076923077,0.726923076923077,0.6461538461538462,0.5653846153846154,0.48461538461538467,0.40384615384615385,0.32307692307692304,0.24230769230769234,0.16153846153846152,0.0807692307692307,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.05,0.9692307692307692,0.8884615384615385,0.8076923076923077,0.726923076923077,0.6461538461538462,0.5653846153846154,0.48461538461538467,0.40384615384615385,0.32307692307692304,0.24230769230769234,0.16153846153846152,0.0807692307692307,{"y":null,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.41,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.3,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.36,"date":1730419200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.08,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.2,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.95,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.05,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
D. Boral Capital Analyst forecast on ENLV
D. Boral Capital
D. Boral Capital
Hold
Downgraded
11/24/25
Enlivex Therapeutics downgraded to Hold from Buy at D. Boral CapitalEnlivex Therapeutics downgraded to Hold from Buy at D. Boral Capital
H.C. Wainwright Analyst forecast on ENLV
H.C. Wainwright
H.C. Wainwright
$7
Buy
833.33%
Upside
Reiterated
09/15/25
Enlivex's Strategic Advancements and Patent Protection Drive Buy Rating for Osteoarthritis TreatmentValuation and Risks. We value Enlivex using a discounted cash flow (DCF)-based methodology. This employs a 12% discount rate, 1% terminal growth rate and 25% effective tax rate. Conservatively, we currently only model Allocetra sales in sepsis and osteoarthritis, although the platform may have applicability in other indications as well. We derive a total firm value of $240M, or a price objective of $7 per share assuming 34.3M fully-diluted shares outstanding as of mid-2026.
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
D. Boral Capital Analyst forecast on ENLV
D. Boral Capital
D. Boral Capital
Hold
Downgraded
11/24/25
Enlivex Therapeutics downgraded to Hold from Buy at D. Boral CapitalEnlivex Therapeutics downgraded to Hold from Buy at D. Boral Capital
H.C. Wainwright Analyst forecast on ENLV
H.C. Wainwright
H.C. Wainwright
$7
Buy
833.33%
Upside
Reiterated
09/15/25
Enlivex's Strategic Advancements and Patent Protection Drive Buy Rating for Osteoarthritis TreatmentValuation and Risks. We value Enlivex using a discounted cash flow (DCF)-based methodology. This employs a 12% discount rate, 1% terminal growth rate and 25% effective tax rate. Conservatively, we currently only model Allocetra sales in sepsis and osteoarthritis, although the platform may have applicability in other indications as well. We derive a total firm value of $240M, or a price objective of $7 per share assuming 34.3M fully-diluted shares outstanding as of mid-2026.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Enlivex

1 Month
xxx
Success Rate
2/5 ratings generated profit
40%
Average Return
+2.46%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of +2.46% per trade.
3 Months
xxx
Success Rate
3/5 ratings generated profit
60%
Average Return
+2.40%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +2.40% per trade.
1 Year
Ram SelvarajuH.C. Wainwright
Success Rate
0/5 ratings generated profit
0%
Average Return
-20.44%
reiterated a buy rating 4 months ago
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -20.44% per trade.
2 Years
xxx
Success Rate
0/5 ratings generated profit
0%
Average Return
-25.24%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -25.24% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ENLV Analyst Recommendation Trends

Rating
Jan 25
Mar 25
Apr 25
Sep 25
Nov 25
Strong Buy
0
1
2
4
3
Buy
0
0
0
0
0
Hold
0
0
0
0
1
Sell
7
4
3
0
0
Strong Sell
0
0
0
0
0
total
7
5
5
4
4
In the current month, ENLV has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ENLV average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

ENLV Financial Forecast

ENLV Earnings Forecast

Next quarter’s earnings estimate for ENLV is -$0.15 with a range of -$0.16 to -$0.15. The previous quarter’s EPS was -$0.25. ENLV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year ENLV has its overall industry.
Next quarter’s earnings estimate for ENLV is -$0.15 with a range of -$0.16 to -$0.15. The previous quarter’s EPS was -$0.25. ENLV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate ― of the time in the same period. In the last calendar year ENLV has its overall industry.
No data currently available

ENLV Sales Forecast

Next quarter’s sales forecast for ENLV is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ENLV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year ENLV has its overall industry.
Next quarter’s sales forecast for ENLV is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. ENLV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates ― of the time in the same period. In the last calendar year ENLV has its overall industry.

ENLV Stock Forecast FAQ

What is ENLV’s average 12-month price target, according to analysts?
Currently, no data Available
What is ENLV’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ENLV, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is ENLV a Buy, Sell or Hold?
      Enlivex Therapeutics Ltd has a consensus rating of Hold which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
        What is Enlivex Therapeutics Ltd’s price target?
        Currently, no data Available
        What do analysts say about Enlivex Therapeutics Ltd?
        Enlivex Therapeutics Ltd’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
          How can I buy shares of ENLV?
          Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.